Transgene to develop a novel immunotherapy against TB

Transgene SA announced that it has been granted a sub-award from Emergent BioSolutions Inc. under its existing grant of approximately $5 million from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH)1. The funding will be used to advance Transgene’s tuberculosis (TB) immunotherapy program.